25 results on '"Mayer-Hamblett, N."'
Search Results
2. P090 Treatment use among SIMPLIFY trial participants through 24 weeks of follow-up
3. Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials
4. 35 Approaches that use historical controls to meet modern needs in cystic fibrosis clinical trials
5. 261 Concentrations of elexacaftor/tezacaftor/ivacaftor in the cystic fibrosis population: Interim analysis of the CHEC-Pharmacokinetics study
6. 43 Cystic fibrosis transmembrane conductance regulator modulator–induced sweat chloride changes in the cystic fibrosis population from the Characterizing Cystic Fibrosis Transmembrane Conductance Regulator–Modulated Changes in Sweat Chloride Study: 2022 Update
7. 47: A new path for CF clinical trials through the use of historical controls
8. 555: Clinical trial interest after establishment of modulator therapy: Interim CHEC-SC survey results
9. Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis
10. Building global development strategies for cf therapeutics during a transitional cftr modulator era
11. Important steps in the journey to highly effective CFTR modulator access for people with CF
12. WS01-3 IV gallium nitrate demonstrates biological activity for chronic Pseudomonas aeruginosa infection in cystic fibrosis
13. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa
14. In statistics we trust: Towards the careful derivation and interpretation of meaningful survival estimates in cystic fibrosis
15. Another step in the journey: From CFTR mutation to sweat chloride concentration to survival
16. 65 Physician assessment of blinded adverse events in RCTs in cystic fibrosis
17. 54 Relationship between rate of percent predicted FEV1 (ppFEV1) decline and baseline and acute change in ppFEV1 in patients (pts) with cystic fibrosis (CF) treated with lumacaftor/ivacaftor (LUM/IVA)
18. Corrigendum to “Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study” [J Cyst Fibros (2015) 632–638]
19. Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study
20. WS02.1 Efficacy of a protocol for eradication of newly acquired MRSA: Results of the STAR-too trial
21. 112 Analysis of long-term use of liposomal amikacin for inhalation (LAI) in patients with cystic fibrosis (CF) who have chronic infection from Pseudomonas aeruginosa
22. WS7.3 Once-daily liposomal amikacin for inhalation is noninferior to twice-daily tobramycin inhalation solution in improving pulmonary function in cystic fibrosis patients with chronic infection due to Pseudomonas aeruginosa
23. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: The early intervention in cystic fibrosis exacerbation (eICE) trial
24. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis
25. The cystic fibrosis therapeutics development network (CF TDN): a paradigm of a clinical trials network for genetic and orphan diseases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.